Lucile Bussot
YOU?
Author Swipe
View article: Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)
Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS) Open
View article: 264 | CD3XCD20 BISPECIFIC ANTIBODIES IN TRANSFORMED WALDENSTRÖM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA
264 | CD3XCD20 BISPECIFIC ANTIBODIES IN TRANSFORMED WALDENSTRÖM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA Open
View article: Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study Open
View article: Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines
Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines Open
View article: CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL
CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL Open
R-CHOP immuno-chemotherapy significantly improved clinical management of diffuse large B-cell lymphoma (DLBCL). However, 30–40% of DLBCL patients still present a refractory disease or relapse. Most of the prognostic markers identified to d…
View article: <scp>c‐MYC</scp> and p53 expression highlight starry‐sky pattern as a favourable prognostic feature in <scp>R‐CHOP</scp>‐treated diffuse large B‐cell lymphoma
<span>c‐MYC</span> and p53 expression highlight starry‐sky pattern as a favourable prognostic feature in <span>R‐CHOP</span>‐treated diffuse large B‐cell lymphoma Open
Diffuse large B‐cell lymphoma (DLBCL) is a clinically heterogeneous entity, in which the first‐line treatment currently consists of an immuno‐chemotherapy regimen (R‐CHOP). However, around 30% of patients will not respond or will relapse. …
View article: Adverse outcome in follicular lymphoma is associated with <i>MYC</i> rearrangements but not <i>MYC</i> extra copies
Adverse outcome in follicular lymphoma is associated with <i>MYC</i> rearrangements but not <i>MYC</i> extra copies Open
Summary Follicular lymphomas (FLs) with MYC rearrangements ( MYC ‐R) and extra copies of MYC ( MYC ‐EC) are rare and the prognosis impact is uncertain. We conducted a retrospective study including 321 FL patients, among whom 259 (81%) had …
View article: Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL Open
International audience
View article: First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study
First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study Open
Historically, double or triple hit lymphoma (DHL and THL) have poor outcomes with conventional chemotherapy, but there is currently no guideline. We report the French experience in managing DHL and THL in first line using collective data o…
View article: Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia
Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia Open
Aplastic anemia is a rare but potentially life-threatening disease that may affect older patients. Data regarding the treatment of aplastic anemia in this ageing population remains scarce. We conducted a retrospective nationwide multicente…